Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more people are using to treat diabetes or lose weight.

The Name of the Year for 2024, according to the American Name Society, is “Ozempic," as in “Ozempic face,” “oat-zempic” and ...

The pharmaceutical industry came up with medicine that stops people from craving processed, addictive foods and the food industry is in a panic.

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Here are some of the major companies whose stocks moved on the week’s news.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...